In this issue:
Assessing the risk of HCC after IFN-free therapy
Discontinuing TDF in noncirrhotic HBeAg– patients
Risk factors for HCC beyond 5 years of ETV or TDF
Vesatolimod safe, well-tolerated in chronic HBV
IFN-free therapy not linked to a higher risk of liver cancer
Glecaprevir + pibrentasvir in stage 4 or 5 CKD & HCV
24-week HBeAg levels may predict response to TDF
Considering organs from HCV-positive donors
OBV/PTV/r ± DSV ± RBV promising in HIV/HCV GT1/4 coinfection
Glecaprevir/pibrentasvir looks promising in GT1/4 treatment failures
Please login below to download this issue (PDF)